Pompe Disease Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential

DelveInsight's, "Pompe Disease Pipeline Insight 2025" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Pompe Disease pipeline landscape. It covers the Pompe Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pompe Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Pompe Disease Treatment Landscape. Click here to read more @ Pompe Disease Pipeline Outlook- https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Pompe Disease Pipeline Report
• In May 2025, Genzyme announced a study to assess the safety and efficacy of avalglucosidase alfa IV infusion in male and female Chinese participants with IOPD who are treatment-naïve or were previously treated with ERT.
• In May 2025, Amicus Therapeutics conducted a Phase 3 study to evaluate the safety, efficacy, PK, PD, and immunogenicity of cipaglucosidase alfa/miglustat treatment in ERT-experienced and ERT-naïve pediatric subjects with IOPD.
• In May 2025, Astellas Pharma Inc. organized a study in subjects with type 2 diabetes mellitus who have inadequate glycemic control on an α-Glucosidase Inhibitor alone. Dosage may be increased during the treatment period if subjects fulfill increasing criteria and the investigators adjudicate that no impact for subjects safety.
• In March 2025, Astellas Gene Therapies announced a study (FORTIS) will evaluate the safety and efficacy of an investigational gene replacement therapy, AT845, in adult subjects with LOPD. Subjects will receive a single dose of AT845 delivered via intravenous (IV) infusion.
• In March 2025, Amicus Therapeutics conducted a study for subjects who completed the ATB200-03 study. The subjects will stay in this study until regulatory approval or marketing authorization and/or commercialization in the participating subject's country.
• In March 2025, Sanofi announced a study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment naïve Pediatric Participants with Infantile-Onset Pompe Disease (IOPD).
• DelveInsight's Pompe Disease pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Pompe Disease treatment.
• The leading Pompe Disease Companies such as Asklepios Biopharmaceutical, GeneCradle Therapeutics, Astellas Gene Therapies, Maze Therapeutics, M6P Therapeutics, Entrada Therapeutics and others.
• Promising Pompe Disease Pipeline Therapies such as ALGLUCOSIDASE ALFA, ACTUS-101, ATB200, AT2221, BMN 701, Duvoglustat, Myozyme, Methotrexate, GC301 and others.

Stay informed about the cutting-edge advancements in Pompe Disease Treatments. Download for updates and be a part of the revolution in Genetic Disorders Care @ Pompe Disease Clinical Trials Assessment- https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pompe Disease Emerging Drugs Profile
• GC301: GeneCradle Therapeutics
GC301 injection is an AAV gene therapy drug designed and developed by Genecradle Therapeutics for the treatment of Pompe disease. It adopts a one-time intravenous injection strategy for widespread systemic expression, aiming to directly compensate for the GAA gene deficiency in tissues such as the liver, heart, skeletal muscles, and central nervous system. In previous clinical trials conducted (IIT+IND), IOPD subjects successfully discontinued enzyme replacement therapy after gene therapy, with varying degrees of improvement in motor ability. Currently, the drug is in the Phase I/II stage of its clinical trial for the treatment of Pompe disease.

• MZE001: Maze Therapeutics
MZE001 is an oral glycogen synthase (GYS1) inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup. GYS1 is an enzyme responsible for glycogen production. MZE001 is currently being evaluated as a potential oral treatment for patients with Pompe disease, as well as other glycogen storage disorders. Currently, the drug is in the Phase I stage of its clinical trial for the treatment of Pompe disease.

Pompe Disease Market Drivers
• Increased Incidence of Pompe Disease
• Increased Research and Clinical Activities

Pompe Disease Market Barriers
• Substantial costs associated with the treatment
• Late Pompe Disease Diagnosis

Get a detailed analysis of the latest innovations in the Pompe Disease pipeline. Explore DelveInsight's expert-driven report today! @ Pompe Disease Unmet Needs- https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pompe Disease Companies
Asklepios Biopharmaceutical, GeneCradle Therapeutics, Astellas Gene Therapies, Maze Therapeutics, M6P Therapeutics, Entrada Therapeutics and others.

The Pompe Disease Pipeline Report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Pompe Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pompe Disease Treatment.
• Pompe Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pompe Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pompe Disease market.

Pompe Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Pompe Disease Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Pompe Disease Treatment by visiting our website. Stay informed about how we're transforming the future of genetic disorders @ Pompe Disease Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Pompe Disease Pipeline Report
• Coverage- Global
• Pompe Disease Companies- Asklepios Biopharmaceutical, GeneCradle Therapeutics, Astellas Gene Therapies, Maze Therapeutics, M6P Therapeutics, Entrada Therapeutics and others.
• Pompe Disease Pipeline Therapies- ALGLUCOSIDASE ALFA, ACTUS-101, ATB200, AT2221, BMN 701, Duvoglustat, Myozyme, Methotrexate, GC301 and others.
• Pompe Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Pompe Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Pompe Disease Pipeline on our website @ Pompe Disease Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.